Should I buy or sell Edgewise Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EWTX shares. View EWTX analyst ratings or view top-rated stocks .

What is Edgewise Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price targets for Edgewise Therapeutics' shares. Their EWTX share price targets range from $23.00 to $48.00. On average, they expect the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 94.2% from the stock's current price. View analysts price targets for EWTX or view top-rated stocks among Wall Street analysts .

How have EWTX shares performed in 2024?

Edgewise Therapeutics' stock was trading at $10.94 at the beginning of 2024. Since then, EWTX shares have increased by 50.6% and is now trading at $16.48. View the best growth stocks for 2024 here .

Are investors shorting Edgewise Therapeutics?

Edgewise Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,720,000 shares, an increase of 27.7% from the March 15th total of 4,480,000 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is currently 5.7 days. Currently, 9.1% of the company's shares are short sold. View Edgewise Therapeutics' Short Interest .

When is Edgewise Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EWTX earnings forecast .

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.03.

What ETFs hold Edgewise Therapeutics' stock?

ETFs with the largest weight of Edgewise Therapeutics (NASDAQ:EWTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Fidelity Disruptive Medicine ETF (FMED) . iShares Neuroscience and Healthcare ETF (IBRN) .

When did Edgewise Therapeutics IPO?

Edgewise Therapeutics (EWTX) raised $150 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free EWTX Stock Alerts

$16.48

+0.11 (+0.67%)

(As of 04/15/2024 ET)

Compare

Today's Range: $16.13
▼
$16.75
50-Day Range: $15.53
▼
$19.97
52-Week Range: $5.12
▼
$20.69

Volume: 403,480 shs
Average Volume: 545,468 shs
Market Capitalization: $1.53 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Get Edgewise Therapeutics alerts:

Edgewise Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 94.2% Upside
$32.00 Price Target
Short Interest: Bearish
9.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.71
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$5 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.76) to ($1.90) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.79 out of 5 stars

Medical Sector

730th out of 928 stocks

Biotechnology Industry

9th out of 20 stocks

3.5

Analyst's Opinion

Consensus Rating
Edgewise Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Edgewise Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.11% of the float of Edgewise Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Edgewise Therapeutics has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in Edgewise Therapeutics has recently increased by 27.68%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Edgewise Therapeutics does not currently pay a dividend.
Dividend Growth
Edgewise Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EWTX.

2.6

News and Social Media Coverage

News Sentiment
Edgewise Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Edgewise Therapeutics this week, compared to 1 article on an average week.
Search Interest
19 people have searched for EWTX on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Edgewise Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Edgewise Therapeutics insiders have bought 145.97% more of their company's stock than they have sold. Specifically, they have bought $4,999,995.00 in company stock and sold $2,032,766.00 in company stock.
Percentage Held by Insiders
31.95% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.76) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Edgewise Therapeutics is -10.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Edgewise Therapeutics is -10.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Edgewise Therapeutics has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Edgewise Therapeutics Stock (NASDAQ:EWTX)

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

EWTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EWTX Stock News Headlines

April 15, 2024 | businesswire.com

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

April 7, 2024 | americanbankingnews.com

Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Up 4.2%

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 28, 2024 | businesswire.com

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

March 27, 2024 | businesswire.com

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

March 5, 2024 | finance.yahoo.com

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

February 28, 2024 | businesswire.com

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

February 26, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

February 25, 2024 | investing.com

Edgewise Therapeutics earnings missed by $0.04, revenue was in line with estimates

February 24, 2024 | msn.com

Edgewise Therapeutics (EWTX) Price Target Increased by 8.00% to 27.54

February 22, 2024 | benzinga.com

Edgewise Therapeutics Stock (NASDAQ:EWTX), Short Interest Report

February 22, 2024 | benzinga.com

Edgewise Therapeutics: Q4 Earnings Insights

February 22, 2024 | msn.com

Edgewise Therapeutics Non-GAAP EPS of $0.47

February 22, 2024 | finance.yahoo.com

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

February 22, 2024 | businesswire.com

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

February 22, 2024 | investing.com

Edgewise Therapeutics Inc (EWTX)

February 22, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Edgewise Therapeutics (EWTX), Bicycle Therapeutics (BCYC)

February 16, 2024 | finance.yahoo.com

EWTX May 2024 30.000 call

February 13, 2024 | finance.yahoo.com

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

February 9, 2024 | finance.yahoo.com

Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?

January 31, 2024 | benzinga.com

How Is The Market Feeling About Edgewise Therapeutics?

January 26, 2024 | finance.yahoo.com

Edgewise Therapeutics Inc CFO R Carruthers Sells 90,000 Shares

January 24, 2024 | finance.yahoo.com

Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet

January 19, 2024 | finance.yahoo.com

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

December 29, 2023 | finance.yahoo.com

Edgewise Therapeutics Inc Director Jonathan Fox Acquires 10,857 Shares

December 19, 2023 | finance.yahoo.com

Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

See More Headlines

Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:EWTX
CUSIP: N/A
CIK: 1710072
Web: www.edgewisetx.com
Phone: 720-262-7002
Fax: N/A
Employees: 88
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.00
High Stock Price Target: $48.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +94.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-100,160,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.06%
Return on Assets: -30.16%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 19.50
Quick Ratio: 19.50

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.53 per share
Price / Book: 3.64

Miscellaneous

Outstanding Shares: 93,110,000
Free Float: 63,362,000
Market Cap: $1.53 billion
Optionable: Optionable
Beta: 0.14

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Peter A. Thompson FACP (Age 64)
M.D., Co-Founder & Independent Chairman
Comp: $73k
Dr. Kevin Koch Ph.D. (Age 64)
President, CEO & Director
Comp: $913.1k
Dr. Badreddin Edris Ph.D. (Age 36)
Co-Founder & Independent Director
Comp: $40k
Dr. Alan J. Russell Ph.D. (Age 54)
Co-Founder, Chief Scientific Officer & Director
Comp: $657.52k
Dr. Joanne M. Donovan M.D. (Age 67)
Ph.D., Chief Medical Officer
Comp: $695.48k
Mr. R. Michael Carruthers (Age 66)
Chief Financial Officer
Comp: $386.01k
Mr. John R. Moore (Age 60)
General Counsel
Dr. Behrad Derakhshan Ph.D. (Age 44)
Chief Business Officer
Comp: $575.53k
Dr. Marc Semigran M.D. (Age 67)
Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EWTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Edgewise Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EWTX shares.
View EWTX analyst ratings or view top-rated stocks.
What is Edgewise Therapeutics' stock price target for 2024?: 4 Wall Street research analysts have issued 1 year price targets for Edgewise Therapeutics' shares. Their EWTX share price targets range from $23.00 to $48.00. On average, they expect the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 94.2% from the stock's current price.
View analysts price targets for EWTX or view top-rated stocks among Wall Street analysts.
How have EWTX shares performed in 2024?: Edgewise Therapeutics' stock was trading at $10.94 at the beginning of 2024. Since then, EWTX shares have increased by 50.6% and is now trading at $16.48.
View the best growth stocks for 2024 here.
Are investors shorting Edgewise Therapeutics?: Edgewise Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,720,000 shares, an increase of 27.7% from the March 15th total of 4,480,000 shares. Based on an average daily volume of 1,010,000 shares, the days-to-cover ratio is currently 5.7 days. Currently, 9.1% of the company's shares are short sold.
View Edgewise Therapeutics' Short Interest.
When is Edgewise Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EWTX earnings forecast.

How were Edgewise Therapeutics' earnings last quarter?: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.03.
What ETFs hold Edgewise Therapeutics' stock?: ETFs with the largest weight of Edgewise Therapeutics (NASDAQ:EWTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) and Fidelity Disruptive Medicine ETF (FMED).iShares Neuroscience and Healthcare ETF (IBRN).
When did Edgewise Therapeutics IPO?: Edgewise Therapeutics (EWTX) raised $150 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO.
How do I buy shares of Edgewise Therapeutics?: Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EWTX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Edgewise Therapeutics (EWTX) Stock Price, News & Analysis

Edgewise Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Edgewise Therapeutics Stock (NASDAQ:EWTX)

EWTX Stock Price History

EWTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

EWTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™